ArticleeLife2022
Parallel evolution of
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 79 citations in OpenAlex.
- Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Article
- Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms.Viruses · 2026Review
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Short-term antagonism between bacteriophages and macrophages decreases with bacteria-phage coevolution.The ISME journal · 2026Article
- Rapid resistance evolution against phage cocktails.The ISME journal · 2026Article
- Detectable effects of bacterial phylogeny on virulence but not phage efficacy in anISME communications · 2026Article
- Immuno-phage synergy driven by fitness costs: turning bacterial phage resistance into therapeutic gain through evolutionary traps.Frontiers in immunology · 2026Review
- Isolation of a complementary bacteriophage from a phage-resistant mutant expands control strategies againstFrontiers in microbiology · 2026Article
- Article
- Community Complexity Does Not Weaken Pairwise Coevolution in a Soil Bacterial Community.Ecology letters · 2025Article
- A case report of bacteriophage therapy for the treatment of lung infection due to carbapenem-resistant Pseudomonas aeruginosa.Scientific reports · 2025Article
- Bacteria-phage (co)evolution is constrained in a synthetic community across multiple bacteria-phage pairs.Microbiology (Reading, England) · 2025Article
- Microbial community structure is affected by phage-resistance associated increases in host density.FEMS microbiology ecology · 2025Article
- Impact of Phage Therapy on Pseudomonas syringae pv. syringae and Plant Microbiome Dynamics Through Coevolution and Field Experiments.Environmental microbiology · 2025Article
- Factors Affecting Phage-Bacteria Coevolution Dynamics.Viruses · 2025Review
- Article
- What, how, and why? - anti-EHEC phages and their application potential in medicine and food industry.Journal of applied genetics · 2025Review
- Phage-phage competition and biofilms affect interactions between two virulent bacteriophages and Pseudomonas aeruginosa.The ISME journal · 2025Article
- Bacteria use exogenous peptidoglycan as a danger signal to trigger biofilm formation.Nature microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
With rising antibiotic resistance, there has been increasing interest in treating pathogenic bacteria with bacteriophages (phage therapy). One limitation of phage therapy is the ease at which bacteria can evolve resistance. Negative effects of resistance may be mitigated when resistance results in reduced bacterial growth and virulence, or when phage coevolves to overcome resistance. Resistance evolution and its consequences are contingent on the bacteria-phage combination and their environmental context, making therapeutic outcomes hard to predict. One solution might be to conduct 'in vitro evolutionary simulations' using bacteria-phage combinations from the therapeutic context. Overall, our aim was to investigate parallels between in vitro experiments and in vivo dynamics in a human participant. Evolutionary dynamics were similar, with high levels of resistance evolving quickly with limited evidence of phage evolution. Resistant bacteria-evolved in vitro and in vivo-had lower virulence. In vivo, this was linked to lower growth rates of resistant isolates, whereas in vitro phage resistant isolates evolved greater biofilm production. Population sequencing suggests resistance resulted from selection on de novo mutations rather than sorting of existing variants. These results highlight the speed at which phage resistance can evolve in vivo, and how in vitro experiments may give useful insights for clinical evolutionary outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.